Bifogade filer
220818 Ascelia Pharma Q2 Report 2022 EN
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Ascelia Pharma AB (publ) (ticker: ACE) today published its half-year financial report for 2022 (January – June 2022), which is now available on the company’s website: https://www.ascelia.com/ir-media/financial-reports/
SIGNIFICANT EVENTS IN Q2 2022
- Food Effect Study shows strong liver imaging enhancement with Orviglance® both with light meal and fasting condition
- Orviglance comparison study to gadolinium presented at ESGAR conference
- New US patent for Oncoral
- Déspina Georgiadou Hedin appointed as new CFO replacing Kristian Borbos
SIGNIFICANT EVENTS AFTER THE PERIOD
- Orviglance Food Effect Study accepted as an oral presentation at the world’s largest radiology conference, RSNA
FINANCIAL SUMMARY Q2 2022
- Operating result of SEK -32.7M (SEK -32.3M)
- Earnings per share of SEK -0.68 (SEK -1.02)
- Cash flow from operations of SEK -32.7M (SEK -30.6M)
- Cash and marketable securities of SEK 208.9M (SEK 319.0M)
FINANCIAL SUMMARY H1 2022
- Operating result of SEK -65.2M (SEK -66.1M)
- Earnings per share of SEK -1.54 (SEK -2.03)
- Cash flow from operations of SEK -60.1M (SEK -53.6M)
- Cash and marketable securities of SEK 208.9M (SEK 319.0M)
“In the last couple of months, we have completed two clinical studies – Hepatic Impairment Study and Food Effect Study – that have run in parallel with the pivotal clinical study SPARKLE with our investigational contrast agent Orviglance. This is a solid step forward in our preparations for regulatory submission and approval of Orviglance. Looking ahead, our prime focus in 2022 is unchanged – to complete the clinical Phase 3 program for Orviglance and continue preparations for commercialization”, said Magnus Corfitzen, CEO at Ascelia Pharma.
A presentation for analysts, investors and media will be held today 18 August at 10:00am CET. The event will be hosted by the company’s CEO Magnus Corfitzen, CFO Kristian Borbos, CCO Julie Waras Brogren and CMO Carl Bjartmar. The presentation will be held in English. The presentation can be followed live via the link: Ascelia Pharma Q2 Report 2022 (streamfabriken.com)
It will also be possible to take part of the audiocast afterwards at the same address or at Ascelia Pharma’s website: https://www.ascelia.com/ir-media/financial-reports/
To participate in the telephone conference, please use the dial-in details shown below:
SE: +46 8 505 583 52
UK: +44 333 3009 265
US: +1 646 7224 904
DK: +45 781 501 09